Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

BioMedPartners, BB Pureos Bioventures lead $12M first close for Basel start-up

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the largest series A for a Swiss biotech since 2015.

Founded in

Read the full 453 word article

How to gain access

Continue reading with a
two-week free trial.